{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T04:07:20Z","timestamp":1745035640602,"version":"3.40.4"},"reference-count":87,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"am","delay-in-days":413,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["K08 AR077689"],"award-info":[{"award-number":["K08 AR077689"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clindermatol.2024.12.007","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T16:36:32Z","timestamp":1734107792000},"page":"153-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genetic and molecular drivers of scleroderma pathogenesis"],"prefix":"10.1016","volume":"43","author":[{"given":"Ian D.","family":"Odell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2024.12.007_bib0001","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0002","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0003","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/archderm.1943.01500210084005","volume":"47","author":"O\u2019Leary","year":"1943","journal-title":"Arch Derm Syphylol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0004","first-page":"361","article-title":"Multiple telangiectasia, Raynaud's phenomenon, sclerodactyly, and subcutaneous calcinosis: a syndrome mimicking hereditary hemorrhagic telangiectasia","volume":"114","author":"Winterbauer","year":"1964","journal-title":"Bull Johns Hopkins Hosp"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0005","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jamadermatol.2023.1729","article-title":"Cutaneous manifestations, clinical characteristics, and prognosis of patients with systemic sclerosis sine scleroderma: data from the international EUSTAR database","volume":"159","author":"Lescoat","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0006","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJM196311282692201","article-title":"Chronic discoid lupus erythematosus","volume":"269","author":"Rothfield","year":"1963","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.1978.tb01954.x","article-title":"A study of lupus erythematosus with particular reference to generalized discoid lupus","volume":"99","author":"O'Loughlin","year":"1978","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0008","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/art.1780310409","article-title":"Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma)","volume":"31","author":"Reimer","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0009","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0010","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","article-title":"Scleroderma renal crisis: patient characteristics and long-term outcomes","volume":"100","author":"Penn","year":"2007","journal-title":"QJM"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0011","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/art.27549","article-title":"Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies","volume":"62","author":"Shah","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0012","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0013","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar4486","article-title":"Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma","volume":"16","author":"Moinzadeh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0014","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3899\/jrheum.160817","article-title":"Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening","volume":"44","author":"Lazzaroni","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/rheumatology\/keh489","article-title":"HLA allelic variants encoding DR11 in diffuse and limited systemic sclerosis in Caucasian women","volume":"44","author":"Loubi\u00e8re","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0016","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/sj.gene.6363734","article-title":"Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP","volume":"2","author":"Gilchrist","year":"2001","journal-title":"Genes Immun"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0017","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/art.24734","article-title":"Clinical and genetic factors predictive of mortality in early systemic sclerosis","volume":"61","author":"Assassi","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0018","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/gene.2014.6","article-title":"MHC associations with clinical and autoantibody manifestations in European SLE","volume":"15","author":"Morris","year":"2014","journal-title":"Genes Immun"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0019","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2009.118174","article-title":"BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians","volume":"69","author":"Rueda","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0020","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1038\/s41467-019-12760-y","article-title":"GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways","volume":"10","author":"L\u00f3pez-Isac","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0021","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ajhg.2013.12.002","article-title":"Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis","volume":"94","author":"Mayes","year":"2014","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0022","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/BOR.0000000000000411","article-title":"Genetic advances in systemic lupus erythematosus: an update","volume":"29","author":"Chen","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0023","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/ng.2395","article-title":"Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis","volume":"44","author":"Liu","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0024","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2018-214127","article-title":"Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases","volume":"78","author":"Acosta-Herrera","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2397198318802763","article-title":"Systemic sclerosis and primary biliary cholangitis: an overlapping entity?","volume":"4","author":"Lepri","year":"2019","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0026","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000163933","article-title":"Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes\/macrophages","volume":"63","author":"Kr\u00e4ling","year":"1995","journal-title":"Pathobiology"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0027","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S2213-2600(18)30508-3","article-title":"Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study","volume":"7","author":"Scott","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0028","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/art.41813","article-title":"Expansion of FCGR3A(+) macrophages, FCN1(+) mo-DC, and plasmacytoid dendritic cells associated with severe skin disease in systemic sclerosis","volume":"74","author":"Xue","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0029","doi-asserted-by":"crossref","first-page":"eaam8458","DOI":"10.1126\/scitranslmed.aam8458","article-title":"Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8","volume":"10","author":"Ah Kioon","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0030","doi-asserted-by":"crossref","first-page":"eabq6691","DOI":"10.1126\/sciimmunol.abq6691","article-title":"Epiregulin is a dendritic cell-derived EGFR ligand that maintains skin and lung fibrosis","volume":"7","author":"Odell","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0031","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1172\/JCI131700","article-title":"Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis","volume":"130","author":"Maehara","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0032","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/0198-8859(96)00091-2","article-title":"Skewing of the CD8+ T-cell repertoire in the lungs of patients with systemic sclerosis","volume":"48","author":"Yurovsky","year":"1996","journal-title":"Hum Immunol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0033","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.4049\/jimmunol.168.7.3649","article-title":"Oligoclonal T cell expansion in the skin of patients with systemic sclerosis","volume":"168","author":"Sakkas","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0034","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2004.027094","article-title":"Early T cell activation in the skin from patients with systemic sclerosis","volume":"64","author":"Kalogerou","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0035","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/ard.52.4.272","article-title":"Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity","volume":"52","author":"Fiocco","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0036","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clim.2011.01.013","article-title":"Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis","volume":"139","author":"Fenoglio","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0037","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13075-020-02383-w","article-title":"Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis","volume":"23","author":"Fox","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0038","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/annrheumdis-2015-207388","article-title":"Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis","volume":"75","author":"Wohlfahrt","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0039","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/art.39437","article-title":"Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis","volume":"68","author":"Mavropoulos","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0040","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/art.20274","article-title":"Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0041","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/0003-4819-102-2-182","article-title":"Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis?","volume":"102","author":"Hawkins","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0042","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/art.30190","article-title":"Mast cells are a source of transforming growth factor beta in systemic sclerosis","volume":"63","author":"Hugle","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0043","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/0003-4819-133-8-200010170-00010","article-title":"Long-term outcomes of scleroderma renal crisis","volume":"133","author":"Steen","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0044","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/art.1780340807","article-title":"Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action","volume":"34","author":"Kahaleh","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0045","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/art.1780340220","article-title":"Elevated plasma levels of endothelin-1 in systemic sclerosis","volume":"34","author":"Yamane","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0046","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0047","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0048","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acr.22018","article-title":"Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis","volume":"65","author":"Tingey","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0049","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","article-title":"Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis","volume":"44","author":"Thompson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0050","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0051","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.30195","article-title":"Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis","volume":"63","author":"Herrick","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0052","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0053","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.semarthrit.2018.03.019","article-title":"Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus","volume":"48","author":"Ingegnoli","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0054","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/2397198318823951","article-title":"Management of Raynaud's phenomenon in systemic sclerosis-a practical approach","volume":"4","author":"Fern\u00e1ndez-Codina","year":"2019","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10067-021-05900-7","article-title":"A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis","volume":"41","author":"Shenavandeh","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0056","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/art.40123","article-title":"The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial","volume":"69","author":"Bello","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0057","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/1573397117666211012105611","article-title":"Evaluation of botulinum toxin type A and its potential effect on exacerbated Raynaud's phenomenon in hospitalized scleroderma patients","volume":"18","author":"Seyedmardani","year":"2022","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0058","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2340\/00015555-2665","article-title":"Efficacy of botulinum toxin B injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis","volume":"97","author":"Motegi","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0059","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/1753193413516242","article-title":"A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma","volume":"39","author":"Uppal","year":"2014","journal-title":"J Hand Surg Eur"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0060","doi-asserted-by":"crossref","first-page":"e15529","DOI":"10.1111\/dth.15529","article-title":"The efficacy of botulinum toxin A in the treatment of Raynaud's phenomenon in systemic sclerosis: A randomized self-controlled trial","volume":"35","author":"Du","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0061","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/1346-8138.13030","article-title":"Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study","volume":"43","author":"Motegi","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0062","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jdcr.2022.06.009","article-title":"Improvement of pterygium inversum unguis and Raynaud phenomenon with interdigital botulinum toxin injections","volume":"26","author":"Kim","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0063","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/ar2598","article-title":"Hypoxia in the pathogenesis of systemic sclerosis","volume":"11","author":"Beyer","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0064","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.1074\/jbc.M112.420711","article-title":"Identification of DEAD-box RNA helicase 6 (DDX6) as a cellular modulator of vascular endothelial growth factor expression under hypoxia","volume":"288","author":"de Vries","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0065","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1136\/ard-2023-225415","article-title":"Single-cell transcriptomes and chromatin accessibility of endothelial cells unravel transcription factors associated with dysregulated angiogenesis in systemic sclerosis","volume":"83","author":"Huang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0066","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12881-017-0380-0","article-title":"Mutation affecting the proximal promoter of endoglin as the origin of hereditary hemorrhagic telangiectasia type 1","volume":"18","author":"Albi\u00f1ana","year":"2017","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0067","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12863-016-0384-3","article-title":"Mutational and clinical analysis of the ENG gene in patients with pulmonary arterial hypertension","volume":"17","author":"Pousada","year":"2016","journal-title":"BMC Genet"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0068","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0069","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0070","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0071","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0072","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13075-015-0721-3","article-title":"Nilotinib (Tasigna\u2122) in treating early diffuse systemic sclerosis: an open-label, pilot clinical trial","volume":"17","author":"Gordon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0073","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","article-title":"Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial","volume":"70","author":"Spiera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0074","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0075","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2306965120","article-title":"IL-6 trans-signaling in a humanized mouse model of scleroderma","volume":"120","author":"Odell","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0076","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2020-219100","article-title":"New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology composite response index in systemic sclerosis","volume":"80","author":"Khanna","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0077","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","article-title":"The European Scleroderma Trials and Research Group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index","volume":"76","author":"Valentini","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0078","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.devcel.2008.12.003","article-title":"Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis","volume":"16","author":"Olson","year":"2009","journal-title":"Dev Cell"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0079","doi-asserted-by":"crossref","first-page":"eaaz5506","DOI":"10.1126\/scitranslmed.aaz5506","article-title":"Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis","volume":"12","author":"Chakraborty","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0080","doi-asserted-by":"crossref","first-page":"e89073","DOI":"10.1172\/jci.insight.89073","article-title":"Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity","volume":"1","author":"Lofgren","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0081","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.26898","article-title":"Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma","volume":"59","author":"Fuchs","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0082","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/jid.2015.174","article-title":"Inhibition of EGFR tyrosine kinase by erlotinib prevents sclerodermatous graft-versus-host disease in a mouse model","volume":"135","author":"Morin","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0083","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1681\/ASN.2011050493","article-title":"Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis","volume":"23","author":"Liu","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0084","doi-asserted-by":"crossref","first-page":"7357","DOI":"10.1038\/s41467-023-43226-x","article-title":"Epidermal growth factor receptor activation is essential for kidney fibrosis development","volume":"14","author":"Cao","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0085","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clindermatol.2011.08.032","article-title":"Chemotherapy-induced iatrogenic injury of skin: new drugs and new concepts","volume":"29","author":"Choi","year":"2011","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0086","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(03)12190-3","article-title":"Severe acute interstitial pneumonia and gefitinib","volume":"361","author":"Inoue","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2024.12.007_bib0087","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/s41423-023-01054-5","article-title":"The role of cellular and molecular neuroimmune crosstalk in gut immunity","volume":"20","author":"Yang","year":"2023","journal-title":"Cell Mol Immunol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X24002724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X24002724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T14:32:34Z","timestamp":1744986754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X24002724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0738081X24002724"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2024.12.007","relation":{},"ISSN":["0738-081X"],"issn-type":[{"type":"print","value":"0738-081X"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic and molecular drivers of scleroderma pathogenesis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2024.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}